Muutke küpsiste eelistusi

E-raamat: ANDA Litigation: Pharmaceutical Patent Litigators

  • Formaat: EPUB+DRM
  • Ilmumisaeg: 17-Feb-2026
  • Kirjastus: American Bar Association
  • Keel: eng
  • ISBN-13: 9781639056644
  • Formaat - EPUB+DRM
  • Hind: 293,96 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: EPUB+DRM
  • Ilmumisaeg: 17-Feb-2026
  • Kirjastus: American Bar Association
  • Keel: eng
  • ISBN-13: 9781639056644

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Representing a compromise in the pharmaceutical industry in balancing patent exclusivity against market competition, the effect of the Drug Price Competition and Patent Term Restoration Act (commonly known as the Hatch-Waxman Act) on controlling the pharmaceutical market remains unsettled. Amendments to the original act included provisions for an abbreviated process for FDA approval of generic versions of patented pharmaceuticals through the filing of an Abbreviated New Drug Application (ANDA) and the right to initiate patent litigation against an applicant. This law has resulted in ANDA litigation cases and a constant struggle to shape the landscape of the patent and regulatory regime governing FDA approved patented and generic drugs. The Hatch-Waxman Act with it amendments is a hybrid of two already complex areas of the law -- U.S. patent law and FDA regulatory law--which makes patent litigation in this area especially complicated and hotly contested.

Now updated and expanded, this Fourth Edition of ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators is a comprehensive guide examining the intersection between the statutory and regulatory scheme governing approval of generic pharmaceuticals and U.S. patent law in the context of Paragraph IV ANDA litigation. In 23 detailed chapters, this single-source reference focuses both on the current and developing law as well as the strategies and tactics employed by the litigants.

ANDA Litigation provides both a ready roadmap for novice litigators in the field as well as more detailed material and strategy to assist the more experienced ANDA litigator. The first part details the Hatch-Waxman Act and how it was implemented. Practical tools in these chapters include: an overview of the drug approval process, including required notice and pre-litigation considerations, and issues related to the timeline of litigation. Following this, the authors explore even deeper into the actual litigation under the act, with topics covering: responses to the complaint, discovery, the work of experts, and patent claim construction and summary judgment.

Further chapters are practice-focused, covering issues including preparing the case for trial, the work of trial, managing the litigation process, and post-trial issues, including appeals to the U.S. Court for the Federal Circuit. Finally, the authors discuss remedies, settlement, and antitrust implications, and the book also includes chapters on regulation and litigation of pharmaceuticals outside the U.S.
Kenneth L. Dorsney, a registered patent attorney, maintains an active practice representing corporate clients and the interests of outside counsel in a wide variety of complex commercial matters, including patent, trademark, trade secret, and copyright litigation, mediation, and dispute resolution in the District of Delaware. A frequent speaker on patent law, Ken has spoken at numerous seminars and law schools on the topic. He is also an active committee member in several associations across the country focused on the practice of intellectual property law and litigation and past Co-Chair of the Intellectual Property Section of the Delaware Chapter of the Federal Bar Association and Chair Emeritus of the Intellectual Property Section of the Delaware State Bar Association. Chief Judge Connolly appointed Ken to serve on the Lawyer Advisory Committee for the U.S.D.C. in Delaware. Mr. Dorsney has a B.A. and B.M.E. from the University of Delaware and a J.D. from the University of Pittsburgh School of Law. He clerked for The Honorable Mary Pat Thynge, U.S. Magistrate Judge for the District of Delaware. After his clerkship with Judge Thynge, Mr. Dorsney clerked for The Honorable Kent A. Jordan, U.S. District Judge for the District of Delaware (in December 2006, Judge Jordan was elevated to the U.S. Court of Appeals for the Third Circuit). Mr. Dorsney is admitted to practice in Delaware, the District of Columbia, and before the U.S. Patent and Trademark Office.